AC Immune (NASDAQ:ACIU) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of AC Immune (NASDAQ:ACIU) in a research note published on Thursday,Zacks reports. The brokerage issued a strong-buy rating on the stock. HC Wainwright also issued estimates for AC Immune’s Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

Several other equities analysts also recently weighed in on the company. Weiss Ratings raised AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Zacks Research cut AC Immune from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 28th. Finally, BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AC Immune presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

AC Immune Trading Down 7.9%

Shares of ACIU opened at $2.11 on Thursday. AC Immune has a twelve month low of $2.02 and a twelve month high of $3.90. The firm has a market capitalization of $214.73 million, a P/E ratio of -4.22 and a beta of 1.64. The firm’s 50-day moving average is $2.55 and its two-hundred day moving average is $2.70.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $3.88 million during the quarter, compared to the consensus estimate of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 97.79%. Analysts predict that AC Immune will post -0.60 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ACIU. AXQ Capital LP acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $25,000. Dimensional Fund Advisors LP grew its holdings in AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after buying an additional 176,701 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after buying an additional 30,035 shares during the last quarter. 51.36% of the stock is owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.